MiMedx pleased with FDA Draft Guidance on Minimal Manipulation of HCT/Ps

MiMedx Group, Inc., the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, commented on the Draft Guidance for Industry on Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products ("HCT/Ps") that the Food and Drug Administration ("FDA") published for comment on December 23, 2014.



from The Medical News http://www.news-medical.net/news/20141231/MiMedx-pleased-with-FDA-Draft-Guidance-on-Minimal-Manipulation-of-HCTPs.aspx